MLYS Mineralys Therapeutics, Inc.
$17.00+6.32%
Last close: · regular session · Last 60 sessions
After-hours $16.87 -0.76% ·
MLYS dilution risk: Low
Automatic S-3ASR shelf since Nov 2025: the company can sell new shares at any time.
- Float
- 63.9M
- Shelf
- S-3ASR
- Last filing
- 10-Q · Nov 4, 2026
Latest SEC filings for MLYS
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| 3 | ||
| 3 | ||
| 8-K | Current report | |
| 3 | ||
| 10-Q | Quarterly report | |
| 8-K | Current report | |
| SCHEDULE 13G/A | ||
| 424B5 | Offering — dilutive |
Dilution today: new offering filings and reverse splits
Dilution risk: low; active automatic shelf (S-3ASR, Nov 2025). Float: 63.9M shares. Latest SEC filing: 10-Q on Nov 4, 2026. MLYS closed at $17.00 (+6.32%) on Nov 4, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MLYS in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 51
- Website: https://mineralystx.com
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Latest MLYS news
- Mineralys outlines December 22 PDUFA timeline while funding lorundrostat launch into 2028 Read article
- Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 Read article
- Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 Read article
Recent dilution filers
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.